Spots Global Cancer Trial Database for A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC
Official Title: A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC
Study ID: NCT02669147
Interventions
Study Description
Brief Summary: This is a prospective observational study to evaluate effectiveness and safety of Enzalutamide for Castration Resistant Prostate Cancer (CRPC) patients who decided to administer Enzalutamide after anti-androgen therapy. CRPC Patients who are observed PSA or disease progression after anti-androgen therapy and decided to administrate Enzalutamide will dose the Enzalutamide 160 mg orally once daily and observed the practical treatment. Total research term is for 4 years, consists of 2-year case registration terms and 2-year observational terms.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Contact Details
Name: Norio Nonomura, MD, Ph.D.
Affiliation: Osaka University Graduate School Of Medicine, Department of Urology
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
